Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12290562 | 0.90 | NOTUM (0.40) | HTR6HTR1AHTR7HTR2CHTR2B | |
| SCHEMBL31492078 | 0.90 | NOTUM (0.40) | HTR6HTR1AHTR7HTR2CHTR2B | |
| SCHEMBL20572109 | 0.80 | HTR2C (0.39) | HTR1AHTR7HTR2CHTR2BHTR2A | |
| Indoline SCHEMBL22344735 | 0.79 | SLC6A4 (0.35) | GAALMNATP53HPGDALOX12 | |
| Indoline SCHEMBL29360339 | 0.77 | — | — | |
| Indoline SCHEMBL5629 | 0.77 | — | — | |
| Indoline SCHEMBL23295083 | 0.75 | HTR2C (0.50) | GAALMNATP53HPGDALOX12 | |
| Indoline SCHEMBL8194348 | 0.75 | HTR2C (0.50) | GAALMNATP53HPGDALOX12 | |
| Indoline SCHEMBL6872936 | 0.75 | HTR2C (0.50) | GAALMNATP53HPGDALOX12 | |
| Indoline SCHEMBL1587228 | 0.75 | HTR2C (0.50) | GAALMNATP53HPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | CERVELLO THERAPEUTICS, LLC. | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248004-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | GAA 3392/4885LMNA 1820/4885TP53 3845/4885 |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | GAA 3392/4885LMNA 1820/4885TP53 3845/4885 |
| US-20200262844-A1 | ROCK KINASE INHIBITORS | ROCK1, ROCK2, RHOA | GAA 1938/4885LMNA 1600/4885TP53 4226/4885 |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | ROCK1, ROCK2, CIT | GAA 3392/4885LMNA 1820/4885TP53 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.